Why doesn’t Typology use hydroquinone?

Hydroquinone (CAS No. 123-31-9) is an aromatic compound belonging to the phenol family, also known by the chemical names 1,4-benzenediol, p-dihydroxybenzene, or 4-hydroxyphenol. Used for several decades, it was first employed as a hair dye before becoming established as a reference depigmenting agent in dermatology. It is particularly used to reduce various forms of hyperpigmentation, such as melasma, lentigines, or post-inflammatory marks.

The effectiveness of hydroquinone is based on a well-known mechanism of action. This active compound works by inhibiting tyrosinase, an enzyme involved in melanogenesis. More specifically, tyrosinase is responsible for converting tyrosine, an amino acid, into melanin, the pigment that gives skin its color. By limiting this production, hydroquinone gradually reduces pigmentation in the treated areas. It can also interfere with oxidative processes within melanocytes, helping to decrease pigment formation.

Hydroquinone is considered one of the most effective active ingredients for lightening pigmented spots, with results generally visible after a few weeks of use.

However, despite this effectiveness, the use of hydroquinone is now strictly regulated. In Europe, it has been banned in cosmetic products intended to lighten the skin since 2001, due to uncertainties regarding its safety. It remains authorized for certain very specific uses, such as in artificial nails, at very low concentrations (≤ 0.02%) and for professional use only. In the United States, hydroquinone is considered a drug when used as a depigmenting agent and is available only with a medical prescription.

Beyond its depigmenting effectiveness, hydroquinone is associated with several well-documented cutaneous adverse effects, which partly explains the caution surrounding its use. The reactions observed can be acute—that is, appearing rapidly after application—or develop more gradually over the course of repeated use. Among the early side effects, the most frequent are skin irritations, with redness, burning sensations, discomfort, and sometimes desquamation (skin peeling). The literature reports a very wide range in the frequency of these irritative reactions, from 0 to 70% when hydroquinone is used as monotherapy, and reaching 10 to 100% when it is combined with other active agents, particularly in more intensive depigmenting regimens.

Other acute reactions have also been reported, such as contact dermatitis or pigmentary disorders, whether in the form of post-inflammatory hyperpigmentation due to skin sensitization caused by hydroquinone, or even hypopigmentation in certain areas. In practical terms, this means that even though hydroquinone is effective on dark spots, its use is not without consequences: it can weaken the skin, especially when used repeatedly, at high concentrations, or on skin that is already sensitized.

Other adverse effects, associated with prolonged use of hydroquinone, are also a cause for concern.

Among these, exogenous ochronosis is the best-documented complication. It is a paradoxical hyperpigmentation, characterized by a gray‑blue discoloration of the skin, sometimes associated with papules or a granular appearance on sun-exposed areas. This condition usually appears after prolonged use of hydroquinone, often over several months or even years, and seems to be promoted by high concentrations or repeated applications without proper supervision.

Several hypotheses have been proposed to explain its origin. Hydroquinone may disrupt certain enzymatic pathways involved in phenol metabolism, notably by inhibiting homogentisate oxidase, which would promote the accumulation of metabolites similar to those observed in endogenous ochronosis. In addition, its repeated oxidation in the skin could lead to the formation of brown‑black polymerized pigments, which gradually deposit within the dermis. This pigment accumulation would explain the persistent and difficult-to-reverse nature of ochronosis.

Other chronic effects have also been described. Nail discoloration, for example, is thought to be related to the oxidation of hydroquinone into reactive quinones, which can polymerize and bind to nail keratin. This process leads to the appearance of brownish or blackish shades, often progressive, especially in cases of repeated contact with the product. More rarely, ocular involvement has been reported, mainly in occupational exposure settings with high concentrations of hydroquinone in the form of vapors or particles. These manifestations include conjunctival melanosis, corresponding to pigment deposits in the eyes, and corneal alterations, possibly related to local oxidation phenomena and oxidative stress.

Overall, these data indicate that repeated exposure to hydroquinone can lead to lasting pigmentary alterations, which may sometimes be opposite to the initially intended effect.

These chronic effects, although variable depending on the conditions of use, raise questions about the ability of hydroquinone to penetrate the body and about its fate once it has been absorbed. In fact, when applied to the skin, hydroquinone is able to cross the skin barrier and partially enter the systemic circulation.

This systemic passage, even partial, explains why hydroquinone has been the subject of numerous toxicological evaluations, particularly regarding its mutagenic and carcinogenic potential.

Several studies, particularlyin vitro, have indeed suggested that hydroquinone can induce DNA damage, notably via the production of reactive oxygen species or the formation of reactive metabolites such as benzoquinone. Studies on isolated human cells have shown an increase in certain genotoxicity markers, such as micronucleus formation or DNA strand breaks, following the addition of hydroquinone to the culture medium. These findings have fueled concerns, especially since hydroquinone is also a metabolite of benzene, a compound that increases the risk of leukemia.

In line with this, some epidemiological data have also suggested an association between exposure to hydroquinone and certain hematologic cancers. An analysis conducted using health data from more than 130,000 patients showed that individuals exposed to hydroquinone had a significantly higher risk of developing lymphoma or leukemia compared with unexposed individuals. These findings suggest a possible link, although the underlying mechanisms remain poorly understood.

However, these data must be interpreted with caution.

The results are heterogeneous and vary across studies. In addition, several studies have shown that these effects can be reduced, or even neutralized, in the presence of enzymatic or antioxidant systems, suggesting that the organism has mechanisms capable of limiting this damage. Furthermore, although some studies have demonstrated an increase in certain tumors, particularly kidney tumors in rats at high doses, these effects appear to depend on the route of administration (often oral or injectable) and on a species-specific susceptibility. Conversely, other studies have not shown a significant increase in tumor risk.

The International Agency for Research on Cancer (IARC) classifies hydroquinone in Group 3, meaning it is “not classifiable as to its carcinogenicity to humans,” due to a lack of sufficient evidence. This classification reflects ongoing uncertainty: there are some signals, but they are not strong enough to formally conclude that hydroquinone poses a carcinogenic risk to humans.

Hydroquinone is controversial not only because of its negative effects on skin and health, but also due to the environmental concerns it raises.

Like other phenolic compounds, it is considered highly toxic to aquatic environments, sometimes at relatively low concentrations. Studies have notably demonstrated marked toxicity in various species used as ecotoxicological indicators, such as Daphnia magna, certain fish, rotifers, and photosynthetic microorganisms. In Daphnia magna, for example, a 48‑hour EC50 value of about 0.15 mg/L has been reported. The EC50 (median effective concentration) corresponds to the concentration of a substance required to produce a biological effect in 50% of the test organisms. The lower this value, the more toxic the substance is.

This toxicity is not limited to visible aquatic organisms. Hydroquinone also affects the microorganisms that are essential to ecosystem functioning, particularly in water and soils. Cyanobacteria, for example, are especially sensitive to it: their photosynthetic activity can be altered, which disrupts primary production at the base of aquatic food webs. In soils, exposure to hydroquinone has been associated with a decrease in the number of cultivable microorganisms as well as with the inhibition of certain key enzymes, such as dehydrogenases and β-glucosidases, which are involved in carbon and organic matter cycles.

These effects of hydroquinone indicate a disruption of microbial metabolism, which can slow down the degradation of organic matter and alter local biological equilibria.

However, it is important to qualify this observation: hydroquinone is not considered a particularly persistent pollutant. Bacteria and fungi are capable of biodegrading it, sometimes quite efficiently, by progressively transforming it into intermediate compounds and then into simpler metabolites. Under aerobic conditions, certain bacteria can directly cleave the aromatic ring of hydroquinone, while other microorganisms first convert it into intermediates such as 1,2,4-trihydroxybenzene before complete degradation. Fungi are also able to incorporate it into their metabolic pathways. This biodegradation helps limit its persistence in natural environments.

That said, the fact that a compound is biodegradable does not mean it is harmless. A substance can be degraded relatively quickly and still cause pronounced toxic effects before it disappears, if it reaches sufficiently high local concentrations or if discharges are repeated. In the case of hydroquinone, it is precisely this combination of high intrinsic toxicity and limited, but not negligible, persistence that justifies a cautious approach. In other words, the natural biodegradation capacities of microorganisms partly mitigate the problem, but are not sufficient to eliminate ecotoxicological concerns related to hydroquinone.

It is therefore both for regulatory reasons and as a matter of health and environmental precaution that we do not use hydroquinone at Typology. In our depigmenting treatments, we prefer to use vitamin C, niacinamide, tranexamic acid, and licorice extract.

• MAIBACH H. I. & al. Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. Journal of Toxicology and Environmental Health (1998).

• ORTONNE J. P. & al. The safety of hydroquinone. Journal of the European Academy of Dermatology and Venereology (2006).

• SNYDER P. W. & al. Final amended safety assessment of hydroquinone as used in cosmetics. International Journal of Toxicology (2010).

• TSE T. W. Hydroquinone for skin lightening: Safety profile, duration of use and when should we stop? Journal of Dermatological Treatment (2010).

• Thèse de Shillah NASAMBU SIMIYU. Effect of chalcone derivatives on melanin biosynthesis in B16-F10 melanoma cells (2012).

• MONTEIRO R. C. & al. A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. Indian Journal of Dermatology (2013).

• LEITAO A. L. & al. Hydroquinone: Environmental pollution, toxicity, and microbial answers. BioMed Research International (2013).

• DRAELOS Z. D. & al. An effective hydroquinone alternative for topical skin lightening. Journal of Cosmetic Dermatology (2020).

• KURNIAWATI Y. & al. Comparison of the effectiveness 3% tranexamic acid cream versus 4% hydroquinone cream for treatment of epidermal type melasma. Journal of Biomedicine & Translational Research (2021).

• WILKERSON M. G. & al. Hydroquinone use increases the risk of leukemia and lymphoma in humans. Journal of Investigative Dermatology (2023).

• KAYE A. D. & al. Topical hydroquinone for hyperpigmentation: A narrative review. Cureus (2023).

• PINO-OTIN M. R. & al. Hydroquinone ecotoxicity: Unveiling risks in soil and river ecosystems with insights into microbial resilience. Toxics (2024).